mRNA vaccines to fight C. difficile infections
mVACS--mRNA Vaccines for C. difficile Suppression
['FUNDING_OTHER'] · UNIVERSITY OF PENNSYLVANIA · NIH-11037943
This study is working on a new type of vaccine using mRNA technology, like the COVID-19 vaccines, to help prevent and treat infections from Clostridioides difficile, which can be a serious health issue, and they’ve seen good results in animals so far!
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11037943 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative mRNA vaccines aimed at preventing and treating infections caused by Clostridioides difficile, a significant public health threat. The approach utilizes modified mRNA technology, similar to that used in COVID-19 vaccines, to create a vaccine that targets the toxins produced by C. difficile. The research team has already demonstrated promising results in animal models, showing that their vaccine formulation can provide protection against lethal doses of the bacteria. However, further improvements are needed to enhance its effectiveness and ensure complete clearance of the infection.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have experienced recurrent C. difficile infections or are at high risk for such infections.
Not a fit: Patients who have never been infected with C. difficile or those with contraindications to vaccination may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to an effective vaccine that significantly reduces the incidence and recurrence of C. difficile infections in patients.
How similar studies have performed: Other research has shown success with mRNA vaccine technology in combating infectious diseases, particularly with COVID-19, indicating a promising avenue for similar approaches against C. difficile.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BUSHMAN, FREDERIC D — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: BUSHMAN, FREDERIC D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.